A study assessing the efficacy and safety of Ramucirumab and paclitaxel in patients with metastatic gastric cancer and adenocarcinoma of the gastrooesophageal junction- A single center experience.
Latest Information Update: 16 Oct 2016
Price :
$35 *
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2016 New trial record